Please login to the form below

Not currently logged in
Email:
Password:

Glenmark settles with Astellas/ Triax

Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin

India-based generics manufacturer Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin.

The suit relates to an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a form of hydrocortisone butyrate cream, Glenmark's generic equivalent of Locoid Lipocream, currently registered by Astellas and licensed to Triax.

Under the settlement and licence agreement, Glenmark will be permitted to market and distribute its version of the cream under a royalty-bearing licence from Astellas and Triax in the US by the end of 2013.

In a statement, Glenmark said it believed it was entitled to 180 days of exclusivity to market the product as the first generic company to file a related ANDA.

According to IMS Health data, Locoid Lipocream had sales of around $38m for 2010.

25th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics